AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced data presentations from ongoing clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) at the virtual ARVO 2021 Annual Meeting. Paul Yang, MD, will present interim data from the XLRP Phase 1/2 trial, highlighting clinically meaningful improvements in macular sensitivity. Mark Pennesi, MD, will present findings from the ACHM Phase 1/2 studies. The sessions are scheduled for May 3 and May 6, 2021, showcasing AGTC's commitment to developing gene therapies for rare eye diseases.

Positive

• Clinically meaningful improvement in macular sensitivity reported in XLRP trial.
• Ongoing Phase 1/2 trials for XLRP and ACHM indicate progress in gene therapy development.

Negative

• None.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials.

Details of XLRP Presentation:

Session Title: Six-Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Lead Presenter: Paul Yang, MD, PhD, Casey Eye Institute, Oregon Health & Science University, Assistant Professor, XLRP Investigator

Session Date: Monday, May 3, 4:30-6:00 PM EDT

Details of ACHM Presentation:

Session Title: 12-Month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Lead Presenter: Mark Pennesi, MD, PhD, Casey Eye Institute, Oregon Health & Science University, Assistant Professor, ACHM Investigator

Session Date: Thursday, May 6, 5:15-6:45 PM EDT

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. 

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

What are the findings from AGTC's XLRP Phase 1/2 trial?

The interim data shows clinically meaningful improvement in macular sensitivity.

When will AGTC present clinical trial data for XLRP and ACHM?

Data will be presented on May 3, 2021 for XLRP and on May 6, 2021 for ACHM.

What is the significance of the AGTC clinical trials?

The trials aim to develop gene therapies for treating rare eye diseases, which can potentially improve vision for patients.

Who leads the presentations for AGTC's clinical trials at ARVO 2021?

Paul Yang, MD, will present XLRP data and Mark Pennesi, MD, will present ACHM data.

How does AGTC's gene therapy aim to address XLRP?

The therapy focuses on subretinal administration to improve retinal function in patients with XLRP.